Ipamorelin vs Tesamorelin: Two Receptors, One Approved Drug

Ipamorelin and tesamorelin both raise growth hormone, but they do it through different receptors — and only one of them is an approved medicine. Tesamorelin is a GHRH analogue with an FDA label for one narrow use; ipamorelin is a ghrelin-receptor agonist that has never been approved for anything.

That difference in status is also a difference in evidence. One has a phase 3 programme behind it; the other has a pharmacokinetic study and two hospital trials in an unrelated indication. This covers what each compound is, how the mechanisms differ, and what the published human data does and does not support.

What each one is

• Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH). It carries the full 44-residue GRF(1-44) sequence with a trans-3-hexenoic acid group attached to the N-terminus, which protects it from enzymatic cleavage. Developed as TH9507, it was approved by the FDA in November 2010 for HIV-associated lipodystrophy (Spooner and Olin 2012). See the tesamorelin profile.

• Ipamorelin is a synthetic pentapeptide — five amino acids — that activates the ghrelin receptor. It was described in 1998 by a Novo Nordisk group as the first selective growth hormone secretagogue (Raun 1998). Its clinical development went towards post-operative ileus rather than growth hormone deficiency, and it was never approved. See the ipamorelin profile.

The size gap is large: tesamorelin is roughly seven times the molecular weight of ipamorelin. They are not variations on one molecule. They belong to two different drug classes that converge on the same hormone.

How they work

Growth hormone release from the pituitary is driven by two stimulatory signals: GHRH, acting on the GHRH receptor, and ghrelin, acting on the growth hormone secretagogue receptor (GHSR-1a). Somatostatin and IGF-1 feedback act as the brakes.

Tesamorelin works on the first pathway. It binds the pituitary GHRH receptor, raises cyclic AMP, and stimulates growth hormone synthesis and release, with a downstream rise in IGF-1. Because the release remains subject to normal somatostatin and IGF-1 feedback, the pattern is described as closer to physiological secretion than injected growth hormone produces.

Ipamorelin works on the second. It is an agonist at GHSR-1a on pituitary somatotrophs and hypothalamic neurons. What set it apart in the original pharmacology was selectivity: in swine, older secretagogues such as GHRP-6 and GHRP-2 raised ACTH and cortisol, while ipamorelin did not, even at doses far above those needed for growth hormone release (Raun 1998). That is an animal finding. In the one human pharmacokinetic study, a single intravenous infusion produced a single episode of growth hormone release peaking at about 40 minutes and declining to negligible levels, with a terminal half-life of about two hours (Gobburu 1999).

Because the two act on different receptors, a GHRH analogue and a ghrelin-receptor agonist are generally described as complementary rather than redundant. That is the rationale behind pairings such as CJC-1295 and ipamorelin. It is a pharmacological argument, not a tested result for tesamorelin plus ipamorelin.

Side by side

Note the WADA row. FDA approval does not remove tesamorelin from the prohibited list; both compounds fall under the peptide hormones and growth factors class.

What the human evidence looks like

The two evidence bases differ in kind, not just in size.

Tesamorelin went through two randomised, placebo-controlled phase 3 trials in people with HIV-associated central fat accumulation. Over 26 weeks it reduced visceral adipose tissue and waist circumference without a clinically significant effect on subcutaneous fat; the reduction was maintained to week 52 in those who continued, and visceral fat re-accumulated in those who stopped (Dhillon 2011; Spooner and Olin 2012). One of the phase 3 trials, NCT00123253, enrolled 412 patients and used 2 mg daily of the original TH9507 formulation. The current Egrifta SV label specifies 1.4 mg by subcutaneous injection once daily for the approved indication; the reformulation changed the delivered amount, so the two figures are not interchangeable.

Research since approval has stayed within HIV. In HIV-associated fatty liver disease, a placebo-controlled trial reported reduced liver fat, and paired biopsies from it were used to map changes in hepatic gene expression (Fourman 2020), and a phase 2 trial of cognition in people with HIV and abdominal obesity found reduced waist circumference but no significant between-group difference in neurocognitive performance (Ellis 2025).

Ipamorelin's human record is short:

1. A pharmacokinetic study in healthy men, eight per dose level, all by intravenous infusion (Gobburu 1999).

2. A phase 2 proof-of-concept trial in post-operative ileus after bowel resection, also intravenous. It was well tolerated, but there was no significant difference from placebo on the key efficacy endpoint (Beck 2014).

3. A second phase 2 ileus trial (NCT01280344), completed with no results posted.

Beyond that, the literature is animal work — for example, reduced cisplatin-induced weight loss in ferrets (Lu 2024). There is no published human study of subcutaneous ipamorelin for growth hormone, body composition or any other purpose it is commonly sold for. The ipamorelin dosage guide covers where the circulating figures come from.

Why they get compared

Mostly because both appear on the same lists. Reviews of GH-axis peptides sold as research compounds group tesamorelin with sermorelin and CJC-1295 as GHRH analogues, place ipamorelin with the secretagogues, and contrast the published evidence with online self-administration protocols (Dominikowski 2026). Sports-medicine reviews cover both alongside unapproved peptides, while noting that rigorous human safety data for the unapproved ones are scarce (Mendias and Awan 2026).

The comparison people usually want is about fat loss. Here the asymmetry is stark: tesamorelin has randomised evidence for reducing visceral fat, but only in HIV-associated lipodystrophy; ipamorelin has no human body-composition data at all. For the closest comparison within the GHRH class, see tesamorelin vs sermorelin; for ipamorelin against the older GHRH analogue, see ipamorelin vs sermorelin.

What the evidence does not show

• Which is better. No trial has compared ipamorelin and tesamorelin directly, in any population or species.

• That tesamorelin's effect generalises. Every phase 3 result comes from people with HIV-associated lipodystrophy. Whether it does the same in anyone else has not been established.

• That ipamorelin changes body composition in humans. Raising growth hormone in a pharmacokinetic study is not the same as an outcome.

• That subcutaneous ipamorelin behaves like the intravenous studies. Route changes absorption and exposure; the published human data are all intravenous.

• That combining them does anything. The two-receptor rationale is plausible. It has not been tested for this pair.

• Long-term safety outside the label. Even for tesamorelin, reviewers at approval flagged the lack of long-term safety data (Spooner and Olin 2012).

Reported side effects

Tesamorelin's adverse effects are documented from controlled trials. Serious treatment-emergent events occurred in under 4% of patients over 26 weeks, and most were injection-site reactions or effects known from growth hormone therapy, such as joint pain, headache and peripheral oedema (Dhillon 2011). The Egrifta SV label adds two warnings: tesamorelin raises IGF-1, which the label says should be monitored because the effects of prolonged elevation are unknown, and it can cause glucose intolerance or diabetes.

Ipamorelin has no equivalent dataset for the way it is used. In the intravenous ileus trial, adverse events were common in both arms and not more frequent with ipamorelin (Beck 2014) — but those were post-surgical inpatients. Reports of headache, flushing or fluid retention from subcutaneous use are uncontrolled. Reviews of the GH-axis research peptides describe a class-wide picture of fluid retention, joint pain, glucose and hormonal disturbances, and injection-site reactions (Dominikowski 2026).

Vial math and handling

The two are handled like other lyophilised peptides: reconstituted gently, refrigerated once mixed, never frozen in solution. The arithmetic of turning a vial and a diluent volume into units on a syringe is covered by the tesamorelin calculator, the CJC-1295 + ipamorelin calculator and the insulin syringe units converter. Those tools answer what a draw contains, not what quantity is appropriate.

The approved tesamorelin product is supplied with its own diluent and instructions, and those take precedence over any general calculator. The reconstitution guide and storage guide cover the general principles.

Frequently asked questions

Is ipamorelin or tesamorelin better for fat loss?

Nobody has tested that question. Tesamorelin reduced visceral abdominal fat in randomised trials, but only in people with HIV-associated lipodystrophy, and the effect reversed when treatment stopped. Ipamorelin has no human body-composition data. For compounds with broader human weight-loss evidence, see peptides for weight loss.

Can ipamorelin and tesamorelin be stacked?

They act on different receptors, which is the usual argument for pairing a GHRH analogue with a secretagogue. No study has examined this combination, so there is no evidence on what it does or on its safety. Combinations with stated evidence grades are listed in the peptide stacks directory.

Is ipamorelin FDA approved?

No. Ipamorelin is not approved for any use, and its completed trials were in post-operative ileus. Tesamorelin is FDA-approved, but only for excess abdominal fat in HIV-associated lipodystrophy.

Which lasts longer, ipamorelin or tesamorelin?

Measured by half-life, ipamorelin: about two hours after intravenous infusion, against 26–38 minutes for tesamorelin. Half-life is not the same as duration of effect, though, and the ipamorelin figure comes from intravenous infusion only.

Are ipamorelin and tesamorelin banned in sport?

Yes. Both are on the WADA Prohibited List under class S2. Tesamorelin's FDA approval does not change that.